Tag:

IPX066

Latest Headlines

Latest Headlines

GSK sets stage for big late-stage drug events, potential blockbusters

GlaxoSmithKline ($GSK) has taken some bold steps to reconfigure its R&D operations, tackling some of the productivity issues that have plagued Big Pharma groups. Over the next year, the

GlaxoSmithKline: Second PhIII Parkinson's drug study turns in winning data

GlaxoSmithKline says that the second of three planned Phase III studies for a reformulated Parkinson's treatment partnered with Impax Laboratories turned in positive numbers, with patients in the

Impax Labs' Parkinson's drug aces late-stage clinical trial

Impax Laboratories ($IPXL) is on a roll. The Hayward, CA-based developer announced Monday evening that the Parkinson's drug it in-licensed from GlaxoSmithKline last year--its second attempt at an